tratado_fibro_quistica

Tratado de Fibrosis Quística
315
En el caso de los enfermos con FQ, la supervivencia es más elevada a corto y largo plazo, en comparación con
otras enfermedades de base. Así, a los 3 meses del trasplante es del 90%, en comparación con el 76% para la
hipertensión pulmonar, el 85% para la fibrosis pulmonar idiopática y el 81% para la EPOC. Esto se debe a que son
más jóvenes y no suelen presentar más comorbilidad asociada relevante (1,2,45-47). Los preliminares del Registro
Español de Trasplante, actualmente en desarrollo, indican que en nuestro medio los enfermos con FQ presentan
una supervivencia superior a la presentada por otros receptores, y cifras de supervivencia superponibles a las del
Registro Internacional (Fig. 5).
CONCLUSIÓN
El TXP debe ser considerado en los enfermos con FQ y enfermedad pulmonar avanzada. En espera de otras alternativas
de tratamiento, el trasplante es la única medida actual capaz de mejorar la calidad de vida y la supervivencia
de estos enfermos.
Si elegimos a los enfermos adecuados y los manejamos de forma óptima antes y después de la intervención, los
resultados del trasplante serán los esperados.
BIBLIOGRAFÍA
1. Román A, Ussetti P, Solé A, Zurbano F,
Borro JM, Vaquero JM, et al. Guidelines
for the Selection of Lung Transplantation
Candidates. Arch Bronconeumol.
2011;47(6):303-309.
2. Christie JD, Edwards LB, Kucheryavaya AY,
Aurora P, Dobbels F, Kirk R, et al. The Registry
of the International Society for Heart
and Lung Transplantation: twenty-seventh
official adult lung and heart-lung transplant
report--2010. J Heart Lung Transplant.
2010;29(10):1104-18.
3. Orens JB, Estenne M, Arcasoy S, Conte JV,
Corris P, Egan JJ, et al. International guidelines
for the selection of lung transplant candidates:
2006 update-a consensus report
from the Pulmonary Scientific Council of
the International Society for Heart and Lung
Transplantation. J Heart Lung Transplant.
2006;25(7):745-55.
4. Kerem E, Reisman J, Corey M, Canny GJ,
Levison H. Prediction of mortality in patients
with cystic fibrosis. N Engl J Med.
1992;326(18):1187-91.
5. Mayer-Hamblett N, Rosenfeld M, Emerson
J, Goss CH, Aitken ML. Developing cystic
fibrosis lung transplant referral criteria using
predictors of 2-year mortality. Am J Respir
Crit Care Med. 2002;166(12 Pt 1):1550-5.
6. Rosenbluth DB, Wilson K, Ferkol T, Schuster
DP. Lung function decline in cystic fibrosis
patients and timing for lung transplantation
referral. Chest. 2004;126(2):412-9.
7. Braun AT, Merlo CA. Cystic fibrosis lung
transplantation. Curr Opin Pulm Med.
2011;17(6):467-72.
8. Belkin RA, Henig NR, Singer LG, Chaparro C,
Rubenstein RC, Xie SX, et al. Risk factors for
death of patients with cystic fibrosis awaiting
lung transplantation. Am J Respir Crit
Care Med. 2006;173(6):659-66.
9. Egan TM, Murray S, Bustami RT, Shearon
TH, McCullough KP, Edwards LB, et al. Development
of the new lung allocation system
in the United States. Am J Transplant.
2006;6(5 Pt 2):1212-27.
10. Hadjiliadis D. Special considerations for patients
with cystic fibrosis undergoing lung transplantation.
Chest. 2007;131(4):1224-31.
11. Lease ED, Zaas DW. Complex bacterial infections
pre and posttransplant. Semin Respir
Crit Care Med. 2010;31(2):234-42.
12. Saiman L, Siegel J; Cystic Fibrosis Foundation
Consensus Conference on Infection
Control Participants. Infection control recommendations
for patients with cystic fibrosis:
Microbiology, important pathogens,
and infection control practices to prevent
patient-to-patient transmission. Am J Infect
Control. 2003;31(3 Suppl):S1-62.
13. Hafkin J, Emily Blumberg E. Infections in lung
transplantation: new insights. Curr Opin Organ
Transplant. 2009;14(5):483-7.
14. Remund K, Best M, Egan J. Infections relevant
to lung transplantation. Proc Am Thorac
Soc. 2009;6(1):94-100.
15. Meachery G, De Soyza A, Nicholson A, Parry
G, Hasan A, Tocewicz K, et al. Outcomes of
lung transplantation for cystic fibrosis in a large
UK cohort. Thorax. 2008;63(8):725-31.
16. Boussaud V, Guillemain R, Grenet D, Coley
N, Souilamas R, Bonnette P, et al. Clinical
outcome following lung transplantation in
cystic fibrosis colonized with Burkholderia
cepacia complex: results from two french
centers. Thorax. 2008;63(8):668-70.
17. De Soyza A, Meachery G, Hester KL, Nicholson
A, Parry G, Tocewicz K, et al. Lung
transplantation for patients with cystic fibrosis
and Burkholderia cepacia complex infection:
a single-center experience. J Heart
Lung Transplant. 2010;29(12):1395-404.
18. Nash EF, Coonar A, Kremer R, Tullis E,
Hutcheon M, Singer LG, et al. Survival
of Burkholderia cepacia sepsis following
lung transplantation in recipients
with cystic fibrosis. Transpl Infect Dis.
2010;12(6):551-4.
19. Gilljam M, Scherstén H, Silverborn M, Jönsson
B, Ericsson Hollsing A. Lung transplantation
in patients with cystic fibrosis and
Mycobacterium abscessus infection. J Cyst
Fibros. 2010;9(4):272-6.
20. Solé A, Vicente R, Morant P, Salavert M,
Pastor A, Morales P. Lung transplantation in
cystic fibrosis. Infectious events. Med Clin
(Barc). 2006;126(7):255-8.
21. Helmi M, Love RB, Welter D, Cornwell RD,
Meyer KC. Aspergillus infection in lung
transplant recipients with cystic fibrosis:
risk factors and outcomes comparison to
other types of transplant recipients. Chest.
2003;123(3):800-8.
22. Arthurs SK, Eid AJ, Deziel PJ, Marshall WF,
Cassivi SD, Walker RC, Razonable RR. The
impact of invasive fungal diseases on survival
after lung transplantation. Clin Transplant.
2010;24(3):341-8.
23. Solé A, Salavert M. Fungal infections after
lung transplantation. Curr Opin Pulm Med.
2009;15(3):243-53.
24. Nash EF, Volling C, Gutiérrez CA, Tullis E,
Coonar A, McRae K, et al. Outcomes of patients
with cystic fibrosis undergoing lung
transplantation with and without cystic fibrosis-associated
liver cirrhosis. Clin Transplant.
2011 Jan 28. doi: 10.1111/j.1399-
0012.2010.01395.x.
25. Brennan AL, Geddes DM, Gyi KM, Baker
EH. Clinical importance of cystic fibrosis-related
diabetes. J Cyst Fibros.
2004;3(4):209-22.